Effects of Antiproteinuric Intervention on Elevated Connective Tissue Growth Factor (CTGF/CCN-2) Plasma and Urine Levels in Nondiabetic Nephropathy | Zendy

Maartje C.J. Slagman | Zendy; Tri Q. Nguyen | Zendy; Femke Waanders | Zendy; Liffert Vogt | Zendy; Marc H. Hemmelder | Zendy; Gozewijn D. Laverman | Zendy; Roel Goldschmeding | Zendy; Gerjan Navis | Zendy

Open Access

Effects of Antiproteinuric Intervention on Elevated Connective Tissue Growth Factor (CTGF/CCN-2) Plasma and Urine Levels in Nondiabetic Nephropathy

Author(s) -

Maartje C.J. Slagman,

Tri Q. Nguyen,

Femke Waanders,

Liffert Vogt,

Marc H. Hemmelder,

Gozewijn D. Laverman,

Roel Goldschmeding,

Gerjan Navis

Publication year - 2011

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.08190910

Subject(s) - ctgf , medicine , endocrinology , losartan , kidney disease , proteinuria , nephropathy , fibrosis , kidney , urology , angiotensin ii , growth factor , blood pressure , diabetes mellitus , receptor

Connective tissue growth factor (CTGF/CCN-2) is a key player in fibrosis. Plasma CTGF levels predict end-stage renal disease and mortality in diabetic chronic kidney disease (CKD), supporting roles in intra- and extrarenal fibrosis. Few data are available on CTGF in nondiabetic CKD. We investigated CTGF levels and effects of antiproteinuric interventions in nondiabetic proteinuric CKD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research